Cargando…
Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
Recent clinical trials revealed that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduce cardiovascular events in type 2 diabetic patients, however, canagliflozin increased limb amputations, an effect not seen with other SGLT2 inhibitors. Since endothelial cell (EC) dysfunction p...
Autores principales: | Behnammanesh, Ghazaleh, Durante, Zane E., Peyton, Kelly J., Martinez-Lemus, Luis A., Brown, Scott M., Bender, Shawn B., Durante, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477081/ https://www.ncbi.nlm.nih.gov/pubmed/31057401 http://dx.doi.org/10.3389/fphar.2019.00362 |
Ejemplares similares
-
Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1
por: Peyton, Kelly J., et al.
Publicado: (2022) -
Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1
por: Behnammanesh, Ghazaleh, et al.
Publicado: (2020) -
Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling
por: Durante, William, et al.
Publicado: (2021) -
Bilirubin Inhibits Neointima Formation and Vascular Smooth Muscle Cell Proliferation and Migration
por: Peyton, Kelly J., et al.
Publicado: (2012) -
Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1α inhibition
por: Wang, Jian, et al.
Publicado: (2023)